Apostolos “Paul” Psychogios, MD, FACMG
Dr. Apostolos “Paul” Psychogios is an American Board of Medical Genetics and Genomics (ABMGG) certified clinical geneticist and a Fellow of the American College of Medical Genetics and Genomics (FACMG). He is the founder of Genome 1st a genome health and precision medicine company (February 2022). Dr. Psychogios completed his residency in medical and clinical genetics at Columbia University Medical Center in New York City and his fellowship in clinical molecular genetics at Harvard Medical School in Boston.
He served as the Chief of Genetics at Dayton Children’s in Dayton, Ohio (2020-2022) and the Chief of Genetics and Metabolism at the Kentucky Children’s in Lexington, KY (2020). He founded the first cardiovascular genetics and genomics service in Kentucky at the UK Gill Heart & Vascular Institute. Dr. Psychogios had previously practiced and held academic appointments in Mayo Clinic, Vanderbilt University Medical Center, and Cleveland Clinic. Before coming to the US, he practiced cardiology in the United Kingdom. He has more than 30 years of clinical experience in internal medicine, cardiology, medical genetics, clinical molecular genetics, and genomic medicine with emphasis in the diagnosis, management, and prevention of heritable disorders and complex undiagnosed conditions in children and adults.
Current practice, areas of interest, and expertise
1. Pediatric, adult genetics, rare and common disorders, undiagnosed disorders, complex familial conditions, with emphasis on pediatric, cancer, psychiatric, cardiovascular, renal genetics and genomics, and pharmacogenetics
2. Transplantation genetics and genomics
3. Orphan drugs, rare disorders, inborn errors of metabolism
4. Whole genome sequencing as a first test in the clinic and urgent care (NICU)
5. Provider-enabled reanalysis of nondiagnostic exome or genome
6. Precision care throughout lifetime (prevention of chronic disease from birth to end of life)
Dr. Psychogios’ practice focuses on promoting precision medicine and health by leveraging genome sequencing and AI/ML technologies. He has been offering Whole Genome Sequencing (WGS) as a first test in the clinic since January 2018 with a combined diagnostic yield of 71% (2022 ACMG Meeting).
Selected recent articles, posters, and presentations
1. Psychogios, A., Trachana, K. Genome Sequencing as a First Tier in the Clinic, eP219 2022 ACMG Annual Clinical Genetics Meeting, Nashville March 22-26
2. Psychogios, A., Roumeliotis, G., Trachana, K., Hood, Leroy. One Stone, Two Birds: How a WGS enabled Diagnostic Journey Transforms into a Precision Population Health Service for the 21st Century. 2021 ACMG Annual Clinical Genetics Meeting, April 13-16